Results 201 to 210 of about 103,961 (275)
Lichen Planopilaris Induced by Checkpoint Inhibitors: A Systematic Review
International Journal of Dermatology, EarlyView.
Niyoosha Yoosefi +2 more
wiley +1 more source
What's new? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken +20 more
wiley +1 more source
Sustained complete remission with third-line nivolumab in advanced renal cell carcinoma: a case report. [PDF]
Küronya Z +4 more
europepmc +1 more source
What's new? A substantial proportion of patients with microsatellite‐unstable gastrointestinal adenocarcinomas do not benefit from immunotherapy. This study demonstrates that microsatellite instability can be reliably detected in plasma‐derived extracellular vesicle DNA from patients with microsatellite‐unstable gastrointestinal cancers.
Aysel Ahadova +16 more
wiley +1 more source
Immune checkpoint inhibitors in resectable non-small cell lung cancer: recent successes and ongoing challenges. [PDF]
Abodunrin FO +4 more
europepmc +1 more source
The Silent Link: Exploring the Impact of Periodontal Diseases on Head and Neck Carcinogenesis
ABSTRACT Objectives Oral dysbiosis can accelerate the progression of head and neck squamous cell carcinoma (HNSCC) by fostering a pro‐inflammatory, immunosuppressive, and metabolically altered environment. This narrative review examines the relationships between periodontitis‐associated bacteria and HNSCC, focusing on their impact on oncogenic pathways,
Yashmin Afshar, Nima Rezaei
wiley +1 more source
Low-Dose Metronomic Chemotherapy With Fixed Low-Dose Nivolumab for Recurrent Cervical Cancer After Radiotherapy: Experience From Routine Clinical Practice. [PDF]
Ramidi GR, Yadav R, Sunny G, Patnaik A.
europepmc +1 more source
ABSTRACT Durvalumab plus tremelimumab (Dur/Tre) is the first‐line treatment for unresectable hepatocellular carcinoma (uHCC). Immune‐mediated adverse events (imAEs) are common; however, the impact of specific imAE types on treatment persistence and outcomes remains unclear.
Tomomitsu Matono +53 more
wiley +1 more source
Impact of Prior mRNA COVID-19 Vaccination on PFS2 in NSCLC Patients Receiving Second-Line Immune Checkpoint Inhibitors: A Real-World Analysis. [PDF]
Çelik S +8 more
europepmc +1 more source
ABSTRACT The high prevalence of gastrointestinal (GI) diseases and their significant impact on the quality of life require new therapeutic strategies. The development of novel therapeutic strategies should prioritize targeting the fundamental pathophysiological mechanisms underlying these diseases, including inflammation, cellular proliferation, and ...
Sayedeh Azimeh Hosseini +7 more
wiley +1 more source

